Abrocitinib, sold under the brand name Cibinqo, is a Janus kinase inhibitor medication used for the treatment of atopic dermatitis.

Routes of administration-oral.

Elimination half-life 2.8–5.2 h

Excretion 1.0–4.4% unchanged in urine

It is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

The most common adverse effects in studies were upper respiratory tract infection, headache, nausea, and diarrhea.

It is a selective inhibitor of the enzyme janus kinase 1 (JAK1).

Pharmacokinetics: quickly absorbed from the gut and generally reaches highest blood plasma concentrations within one hour. 

Only 1.0 to 4.4% of the dose are found unmetabolized in the urine.

Leave a Reply

Your email address will not be published. Required fields are marked *